Bicycle Therapeutics' Duravelo-2 Trial Shows Lower Toxicity, Comparable Efficacy in mUC
BCYC is trading near its 52-week low of $4.24 (3.8% above the low).
Summary
Bicycle Therapeutics announced initial Duravelo-2 clinical data for its zelenectide program in metastatic urothelial cancer (mUC), showing a 58% BICR-confirmed Overall Response Rate (ORR) and a differentiated safety profile with lower toxicity. This positive data for zelenectide is notable given the company's prior strategic announcements in March and April, which included deprioritizing this program and focusing on nuzefatide pevedotin. The favorable safety profile, combined with comparable efficacy, could lead to a re-evaluation of the program's potential or attract partnership interest, which is significant for the company, currently trading near its 52-week low.
At the time of this announcement, BCYC was trading at $4.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $308.1M. The 52-week trading range was $4.24 to $9.36. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.